trending Market Intelligence /marketintelligence/en/news-insights/trending/zx3ftdfwkgc8ymrtzeqexa2 content esgSubNav
In This List

Merck & Co.'s Zerbaxa succeeds in phase 3 pneumonia trial


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Merck & Co.'s Zerbaxa succeeds in phase 3 pneumonia trial

SNL Image

Merck & Co. Inc. said the phase 3 trial of its antibiotic Zerbaxa in certain types of pneumonia met its main goal.

Results from the phase 3 study, dubbed Aspect-NP, showed that Zerbaxa, or ceftolozane and tazobactam, worked as well as meropenem in treating patients with either ventilated hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia.

Meropenem is sold by Merck & Co. and AstraZeneca PLC as Invanz and Merrem, respectively.

Zerbaxa is used as a single treatment for treating complicated urinary tract infections caused by certain Gram-negative microorganisms and combined with metronidazole for treating complicated intra-abdominal infections caused by certain Gram-negative and Gram-positive microorganisms.

The Kenilworth, N.J.-based drugmaker plans to seek approval from the U.S. Food and Drug Administration and European Medicines Agency for the new indication based on the results of the phase 3 trial.